Olson DaiWai M, Cox Margueritte, Constable Mark, Britz Gavin W, Lin Cheryl B, Zimmer Louise O, Fonarow Gregg C, Schwamm Lee H, Peterson Eric D
Questions or comments about this article may be directed to DaiWai M. Olson, PhD RN CCRN, at
J Neurosci Nurs. 2014 Oct;46(5):267-73. doi: 10.1097/JNN.0000000000000082.
No instruments are currently available to help health systems identify target areas for reducing door-to-needle times for the administration of intravenous tissue plasminogen activator to eligible patients with ischemic stroke. A 67-item Likert-scale survey was administered by telephone to stroke personnel at 252 U.S. hospitals participating in the "Get With The Guidelines-Stroke" quality improvement program. Factor analysis was used to refine the instrument to a four-factor 29-item instrument that can be used by hospitals to assess their readiness to administer intravenous tissue plasminogen activator within 60 minutes of patient hospital arrival.
目前尚无工具可帮助卫生系统确定目标领域,以缩短对符合条件的缺血性中风患者静脉注射组织型纤溶酶原激活剂的门针时间。对参与“遵循卒中指南”质量改进计划的252家美国医院的卒中医护人员进行了电话调查,调查采用67项李克特量表。通过因子分析将该工具优化为一个包含29个项目的四因子工具,医院可用其评估在患者入院60分钟内静脉注射组织型纤溶酶原激活剂的准备情况。